Literature DB >> 2491748

Isolation of Chinese hamster ovary cell mutants deficient in excision repair and mitomycin C bioactivation.

A M Dulhanty1, M Li, G F Whitmore.   

Abstract

Mitomycin C (MMC), a bifunctional alkylating agent, requires metabolic reduction to become biologically active. We have identified a series of genetically related Chinese hamster ovary cell lines which span approximately three orders of magnitude in the concentration of MMC required for cell killing. Many mechanisms, including drug transport, drug activation, drug detoxification, and the elimination, or repair, of drug-induced lesions, may contribute to the level of drug resistance in cells. By exploring each of the above mechanisms in the various Chinese hamster ovary cell lines, we have been able to classify these cell lines into four categories. Proceeding from least resistant to most resistant to MMC, the cell lines are: (a) proficient in the bioreduction of MMC and deficient in DNA excision repair; (b) deficient in some aspects of MMC bioreduction and deficient in repair; (c) bioreduction and repair proficient; and (d) bioreduction deficient and repair proficient.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2491748

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  P-glycoprotein-expressing tumor cells are resistant to anticancer drugs in human gastrointestinal cancer.

Authors:  T Hotta; H Tanimura; M Iwahashi; M Tani; T Tsunoda; K Noguchi; S Mizobata; K Arii; H Terasawa; M Nakamori; H Yamaue
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

Review 2.  Multiple drug resistance and intermediate filaments.

Authors:  A E Cress; W S Dalton
Journal:  Cancer Metastasis Rev       Date:  1996-12       Impact factor: 9.264

Review 3.  Role of DNA repair in the mechanisms of cell resistance to alkylating agents and cisplatin.

Authors:  P Calsou; B Salles
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 4.  Cellular pharmacology of quinone bioreductive alkylating agents.

Authors:  S Rockwell; A C Sartorelli; M Tomasz; K A Kennedy
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

5.  Molecular cloning of the human nucleotide-excision-repair gene ERCC4.

Authors:  L H Thompson; K W Brookman; C A Weber; E P Salazar; J T Reardon; A Sancar; Z Deng; M J Siciliano
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

6.  Comparison of uptake of mitomycin C and KW-2149 by murine P388 leukemia cells sensitive or resistant to mitomycin C.

Authors:  E Kobayashi; M Okabe; M Kono; H Arai; M Kasai; K Gomi; J H Lee; M Inaba; T Tsuruo
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Modulation of sensitivity to mitomycin C and a dithiol analogue by tempol in non-small-cell lung cancer cell lines under hypoxia.

Authors:  T Bando; K Kasahara; K Shibata; Y Numata; U Heki; H Shirasaki; K Iwasa; M Fujimura; T Matsuda
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

Review 8.  DT-diaphorase in activation and detoxification of quinones. Bioreductive activation of mitomycin C.

Authors:  D Ross; D Siegel; H Beall; A S Prakash; R T Mulcahy; N W Gibson
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

Review 9.  Cellular approaches to bioreductive drug mechanisms.

Authors:  A M Rauth; R S Marshall; B L Kuehl
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

10.  DT-diaphorase: questionable role in mitomycin C resistance, but a target for novel bioreductive drugs?

Authors:  P Workman; M I Walton; G Powis; J J Schlager
Journal:  Br J Cancer       Date:  1989-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.